Please login to the form below

Not currently logged in
Email:
Password:

Immodulon Therapeutics appointments two new board of directors

Anthony Bolton and Sir Simon Robertson join the biopharma firm

Sir Simon RobertsonImmodulon Therapeutics, a privately held, late-stage biopharmaceutical company focused on immuno-oncology has made two new senior appointments to its board of directors.

Anthony Bolton, one of the UK's most successful investment fund managers and Sir Simon Robertson (pictured), deputy chairman of HSBC, will join Immodulon as non-executive directors with immediate effect.

Bolton joined Fidelity in 1979. He has managed several Fidelity funds including the Fidelity Special Situations that he ran for 28 years up to 2007. During this time the fund became the largest unit trust in the UK and achieved annual growth of almost 20%. 

More recently, he wrote an investment book 'Investing Against the Tide' and managed Fidelity China Special Situations PLC whilst based in Hong Kong for four years.

Although he retired from fund management in 2014 he remains a board member and adviser at Fidelity as well as a trustee of its charitable foundations.

Sir Simon joined the board of HSBC in 2006 and has served on a number of board committees. 

He has an extensive background in international corporate advisory work and a wealth of experience in mergers and acquisitions and financial markets. 

His international experience includes working in France, Germany, the UK and the US. He was knighted in the 2010 Queen's birthday honours list in recognition of his services to business.

16th June 2015

From: Research

Share

Tags

PMEA Awards 2020

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
claire@dovetailstrategies.com

About Dovetail We’re award-winning specialists in healthcare collaboration that makes patients’ lives better. Combining expertise with a passion for collaboration,...

Latest intelligence

2020 - a year to remember or forget?
2020 and the Covid pandemic brought immense challenges, and the need for change felt like it happened overnight. What have we learned and what does the future of agency working...
Gilead Headquarters
The search for effective drug treatments for COVID-19
PME talks to Julian Cole, Senior Director, Medical Affairs at Gilead Sciences...
PME Jan cover
AstraZeneca’s focus on diagnosing and managing chronic kidney disease
People living with chronic kidney disease are in urgent need of new and improved approaches to diagnosis and care...

Infographics